160 related articles for article (PubMed ID: 32382021)
1. Micro-Nano formulation of bile-gut delivery: rheological, stability and cell survival, basal and maximum respiration studies.
Wagle SR; Walker D; Kovacevic B; Gedawy A; Mikov M; Golocorbin-Kon S; Mooranian A; Al-Salami H
Sci Rep; 2020 May; 10(1):7715. PubMed ID: 32382021
[TBL] [Abstract][Full Text] [Related]
2. The effect of a tertiary bile acid, taurocholic acid, on the morphology and physical characteristics of microencapsulated probucol: potential applications in diabetes: a characterization study.
Mooranian A; Negrulj R; Arfuso F; Al-Salami H
Drug Deliv Transl Res; 2015 Oct; 5(5):511-22. PubMed ID: 26242686
[TBL] [Abstract][Full Text] [Related]
3. Novel chenodeoxycholic acid-sodium alginate matrix in the microencapsulation of the potential antidiabetic drug, probucol. An in vitro study.
Mooranian A; Negrulj R; Mikov M; Golocorbin-Kon S; Arfuso F; Al-Salami H
J Microencapsul; 2015; 32(6):589-97. PubMed ID: 26190214
[TBL] [Abstract][Full Text] [Related]
4. Multicompartmental, multilayered probucol microcapsules for diabetes mellitus: Formulation characterization and effects on production of insulin and inflammation in a pancreatic β-cell line.
Mooranian A; Negrulj R; Arfuso F; Al-Salami H
Artif Cells Nanomed Biotechnol; 2016 Nov; 44(7):1642-53. PubMed ID: 26377035
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological and Biological Study of Microencapsulated Probucol-Secondary Bile Acid in a Diseased Mouse Model.
Wagle SR; Kovacevic B; Ionescu CM; Walker D; Jones M; Carey L; Takechi R; Mikov M; Mooranian A; Al-Salami H
Pharmaceutics; 2021 Aug; 13(8):. PubMed ID: 34452184
[TBL] [Abstract][Full Text] [Related]
6. Novel nano-encapsulation of probucol in microgels: scanning electron micrograph characterizations, buoyancy profiling, and antioxidant assay analyses.
Mooranian A; Zamani N; Mikov M; Goločorbin-Kon S; Stojanovic G; Arfuso F; Al-Salami H
Artif Cells Nanomed Biotechnol; 2018; 46(sup3):S741-S747. PubMed ID: 30260253
[TBL] [Abstract][Full Text] [Related]
7. Eudragit
Mooranian A; Zamani N; Mikov M; Goločorbin-Kon S; Stojanovic G; Arfuso F; Al-Salami H
Ther Deliv; 2018 Nov; 9(11):811-821. PubMed ID: 30444461
[TBL] [Abstract][Full Text] [Related]
8. Microencapsulation as a novel delivery method for the potential antidiabetic drug, Probucol.
Mooranian A; Negrulj R; Chen-Tan N; Al-Sallami HS; Fang Z; Mukkur TK; Mikov M; Golocorbin-Kon S; Fakhoury M; Watts GF; Matthews V; Arfuso F; Al-Salami H
Drug Des Devel Ther; 2014; 8():1221-30. PubMed ID: 25246766
[TBL] [Abstract][Full Text] [Related]
9. Stability and biological testing of taurine-conjugated bile acid antioxidant microcapsules for diabetes treatment.
Mooranian A; Zamani N; Mikov M; Goločorbin-Kon S; Stojanovic G; Arfuso F; Al-Salami H
Ther Deliv; 2019 Feb; 10(2):99-106. PubMed ID: 30729887
[TBL] [Abstract][Full Text] [Related]
10. Pharmacological and Advanced Cell Respiration Effects, Enhanced by Toxic Human-Bile Nano-Pharmaceuticals of Probucol Cell-Targeting Formulations.
Wagle SR; Kovacevic B; Walker D; Ionescu CM; Jones M; Stojanovic G; Kojic S; Mooranian A; Al-Salami H
Pharmaceutics; 2020 Jul; 12(8):. PubMed ID: 32751051
[TBL] [Abstract][Full Text] [Related]
11. Probucol release from novel multicompartmental microcapsules for the oral targeted delivery in type 2 diabetes.
Mooranian A; Negrulj R; Al-Sallami HS; Fang Z; Mikov M; Golocorbin-Kon S; Fakhoury M; Watts GF; Matthews V; Arfuso F; Lambros A; Al-Salami H
AAPS PharmSciTech; 2015 Feb; 16(1):45-52. PubMed ID: 25168450
[TBL] [Abstract][Full Text] [Related]
12. An optimized probucol microencapsulated formulation integrating a secondary bile acid (deoxycholic acid) as a permeation enhancer.
Mooranian A; Negrulj R; Chen-Tan N; Watts GF; Arfuso F; Al-Salami H
Drug Des Devel Ther; 2014; 8():1673-83. PubMed ID: 25302020
[TBL] [Abstract][Full Text] [Related]
13. Bile acid bio-nanoencapsulation improved drug targeted-delivery and pharmacological effects via cellular flux: 6-months diabetes preclinical study.
Mooranian A; Raj Wagle S; Kovacevic B; Takechi R; Mamo J; Lam V; Watts GF; Mikov M; Golocorbin-Kon S; Stojanovic G; Al-Sallami H; Al-Salami H
Sci Rep; 2020 Jan; 10(1):106. PubMed ID: 31919411
[TBL] [Abstract][Full Text] [Related]
14. Swelling, mechanical strength, and release properties of probucol microcapsules with and without a bile acid, and their potential oral delivery in diabetes.
Negrulj R; Mooranian A; Chen-Tan N; Al-Sallami HS; Mikov M; Golocorbin-Kon S; Fakhoury M; Watts GF; Arfuso F; Al-Salami H
Artif Cells Nanomed Biotechnol; 2016 Aug; 44(5):1290-7. PubMed ID: 25811999
[TBL] [Abstract][Full Text] [Related]
15. Antioxidant properties of probucol released from mesoporous silica.
Lau M; Giri K; Garcia-Bennett AE
Eur J Pharm Sci; 2019 Oct; 138():105038. PubMed ID: 31398394
[TBL] [Abstract][Full Text] [Related]
16. The biological effects of the hypolipidaemic drug probucol microcapsules fed daily for 4 weeks, to an insulin-resistant mouse model: potential hypoglycaemic and anti-inflammatory effects.
Mooranian A; Negrulj R; Takechi R; Mamo J; Al-Sallami H; Al-Salami H
Drug Deliv Transl Res; 2018 Jun; 8(3):543-551. PubMed ID: 29313296
[TBL] [Abstract][Full Text] [Related]
17. Characterization of a novel bile acid-based delivery platform for microencapsulated pancreatic β-cells.
Mooranian A; Negrulj R; Arfuso F; Al-Salami H
Artif Cells Nanomed Biotechnol; 2016; 44(1):194-200. PubMed ID: 25014218
[TBL] [Abstract][Full Text] [Related]
18. G5-PEG PAMAM dendrimer incorporating nanostructured lipid carriers enhance oral bioavailability and plasma lipid-lowering effect of probucol.
Qi R; Li YZ; Chen C; Cao YN; Yu MM; Xu L; He B; Jie X; Shen WW; Wang YN; van Dongen MA; Liu GQ; Banaszak Holl MM; Zhang Q; Ke X
J Control Release; 2015 Jul; 210():160-8. PubMed ID: 26003044
[TBL] [Abstract][Full Text] [Related]
19. Probucol Self-Emulsified Drug Delivery System: Stability Testing and Bioavailability Assessment in Human Volunteers.
Zaghloul A; Lila A; Abd-Allah F; Nada A
Curr Drug Deliv; 2019; 16(4):325-330. PubMed ID: 30588885
[TBL] [Abstract][Full Text] [Related]
20. Bio Micro-Nano Technologies of Antioxidants Optimised Their Pharmacological and Cellular Effects, ex vivo, in Pancreatic β-Cells.
Mooranian A; Zamani N; Mikov M; Goločorbin-Kon S; Stojanovic G; Arfuso F; Kovacevic B; Al-Salami H
Nanotechnol Sci Appl; 2020; 13():1-9. PubMed ID: 32021126
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
